AU2017283546C1 - Use of myostatin inhibitors and combination therapies - Google Patents

Use of myostatin inhibitors and combination therapies Download PDF

Info

Publication number
AU2017283546C1
AU2017283546C1 AU2017283546A AU2017283546A AU2017283546C1 AU 2017283546 C1 AU2017283546 C1 AU 2017283546C1 AU 2017283546 A AU2017283546 A AU 2017283546A AU 2017283546 A AU2017283546 A AU 2017283546A AU 2017283546 C1 AU2017283546 C1 AU 2017283546C1
Authority
AU
Australia
Prior art keywords
myostatin
muscle
smn
subject
sma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017283546A
Other languages
English (en)
Other versions
AU2017283546A1 (en
AU2017283546B2 (en
Inventor
Yung CHYUNG
Adriana Donovan
Kimberly LONG
Michelle STRAUB
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scholar Rock Inc
Original Assignee
Scholar Rock Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59093642&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2017283546(C1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Scholar Rock Inc filed Critical Scholar Rock Inc
Publication of AU2017283546A1 publication Critical patent/AU2017283546A1/en
Application granted granted Critical
Publication of AU2017283546B2 publication Critical patent/AU2017283546B2/en
Priority to AU2020210134A priority Critical patent/AU2020210134B2/en
Publication of AU2017283546C1 publication Critical patent/AU2017283546C1/en
Priority to AU2021261907A priority patent/AU2021261907B2/en
Priority to AU2024203412A priority patent/AU2024203412A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Dermatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2017283546A 2016-06-13 2017-06-13 Use of myostatin inhibitors and combination therapies Active AU2017283546C1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2020210134A AU2020210134B2 (en) 2016-06-13 2020-07-27 Use of myostatin inhibitors and combination therapies
AU2021261907A AU2021261907B2 (en) 2016-06-13 2021-11-04 Use of myostatin inhibitors and combination therapies
AU2024203412A AU2024203412A1 (en) 2016-06-13 2024-05-22 Use of myostatin inhibitors and combination therapies

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201662349596P 2016-06-13 2016-06-13
US62/349,596 2016-06-13
US201762470157P 2017-03-10 2017-03-10
US62/470,157 2017-03-10
US201762486934P 2017-04-18 2017-04-18
US62/486,934 2017-04-18
US201762511702P 2017-05-26 2017-05-26
US62/511,702 2017-05-26
US201762512254P 2017-05-30 2017-05-30
US62/512,254 2017-05-30
PCT/US2017/037332 WO2017218592A1 (en) 2016-06-13 2017-06-13 Use of myostatin inhibitors and combination therapies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2020210134A Division AU2020210134B2 (en) 2016-06-13 2020-07-27 Use of myostatin inhibitors and combination therapies

Publications (3)

Publication Number Publication Date
AU2017283546A1 AU2017283546A1 (en) 2018-12-20
AU2017283546B2 AU2017283546B2 (en) 2020-05-21
AU2017283546C1 true AU2017283546C1 (en) 2020-11-19

Family

ID=59093642

Family Applications (4)

Application Number Title Priority Date Filing Date
AU2017283546A Active AU2017283546C1 (en) 2016-06-13 2017-06-13 Use of myostatin inhibitors and combination therapies
AU2020210134A Active AU2020210134B2 (en) 2016-06-13 2020-07-27 Use of myostatin inhibitors and combination therapies
AU2021261907A Active AU2021261907B2 (en) 2016-06-13 2021-11-04 Use of myostatin inhibitors and combination therapies
AU2024203412A Pending AU2024203412A1 (en) 2016-06-13 2024-05-22 Use of myostatin inhibitors and combination therapies

Family Applications After (3)

Application Number Title Priority Date Filing Date
AU2020210134A Active AU2020210134B2 (en) 2016-06-13 2020-07-27 Use of myostatin inhibitors and combination therapies
AU2021261907A Active AU2021261907B2 (en) 2016-06-13 2021-11-04 Use of myostatin inhibitors and combination therapies
AU2024203412A Pending AU2024203412A1 (en) 2016-06-13 2024-05-22 Use of myostatin inhibitors and combination therapies

Country Status (20)

Country Link
US (2) US10946036B2 (enExample)
EP (3) EP3785728A3 (enExample)
JP (4) JP6823167B2 (enExample)
KR (4) KR102271635B1 (enExample)
AU (4) AU2017283546C1 (enExample)
CL (1) CL2018003588A1 (enExample)
CY (1) CY1123678T1 (enExample)
DK (1) DK3368069T3 (enExample)
ES (1) ES2830440T3 (enExample)
HR (1) HRP20201764T1 (enExample)
HU (1) HUE051480T2 (enExample)
IL (2) IL301468A (enExample)
LT (1) LT3368069T (enExample)
MY (2) MY185614A (enExample)
PE (1) PE20190205A1 (enExample)
PT (1) PT3368069T (enExample)
RS (1) RS61090B1 (enExample)
SI (1) SI3368069T1 (enExample)
SM (1) SMT202000598T1 (enExample)
WO (1) WO2017218592A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2014DN10515A (enExample) 2006-03-31 2015-08-21 Chugai Pharmaceutical Co Ltd
MX369784B (es) 2007-09-26 2019-11-21 Chugai Pharmaceutical Co Ltd Metodo de modificacion del punto isoelectrico de anticuerpos mediante la sustitucion de aminoacidos en region de determinacion de complementariedad (cdr).
PT2708559T (pt) 2008-04-11 2018-05-16 Chugai Pharmaceutical Co Ltd Molécula de ligação ao antigénio capaz de se ligar repetidamente a duas ou mais moléculas de antigénio
TWI654204B (zh) 2010-11-30 2019-03-21 中外製藥股份有限公司 具有鈣依存性的抗原結合能力之抗體
JP6774164B2 (ja) 2012-08-24 2020-10-21 中外製薬株式会社 マウスＦｃγＲＩＩ特異的Ｆｃ抗体
CA2908350C (en) 2013-04-02 2023-08-08 Futa Mimoto Fc region variant
EP3215175A4 (en) 2014-11-06 2018-06-27 Scholar Rock, Inc. Anti-pro/latent-myostatin antibodies and uses thereof
AR103161A1 (es) 2014-12-19 2017-04-19 Chugai Pharmaceutical Co Ltd Anticuerpos antimiostatina y regiones fc variantes así como métodos de uso
EP3816179A3 (en) 2015-02-05 2021-08-04 Chugai Seiyaku Kabushiki Kaisha Fc region variant comprising a modified fcrn-binding domain
SMT202500263T1 (it) 2015-09-15 2025-09-12 Scholar Rock Inc Anticorpi anti-pro-miostatina/miostatina latente e loro usi
US11359009B2 (en) 2015-12-25 2022-06-14 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
SG11201805709RA (en) 2016-01-08 2018-07-30 Scholar Rock Inc Anti-pro/latent myostatin antibodies and methods of use thereof
EP3785728A3 (en) 2016-06-13 2021-04-28 Scholar Rock, Inc. Use of myostatin inhibitors and combination therapies
MY193497A (en) * 2016-06-17 2022-10-17 Chugai Pharmaceutical Co Ltd Anti-myostatin antibodies and methods of use
CN116251182A (zh) 2016-08-05 2023-06-13 中外制药株式会社 用于预防或治疗il-8相关疾病的组合物
JOP20190085A1 (ar) 2016-10-20 2019-04-17 Biogen Ma Inc طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة
US11857599B2 (en) 2017-04-03 2024-01-02 Acceleron Pharma Inc. Compositions and methods for treating spinal muscular atrophy
SG10202002990XA (en) 2017-08-04 2020-05-28 Skyhawk Therapeutics Inc Methods and compositions for modulating splicing
WO2019170930A1 (es) * 2018-03-09 2019-09-12 Universitat De Lleida Tratamiento para la atrofia muscular espinal
WO2019204369A1 (en) * 2018-04-17 2019-10-24 Applied Stemcell, Inc. Compositions and methods for treating spinal muscular atrophy
SG11202108099WA (en) 2019-01-30 2021-08-30 Scholar Rock Inc LTBP COMPLEX-SPECIFIC INHIBITORS OF TGFβ AND USES THEREOF
KR20210135241A (ko) 2019-02-05 2021-11-12 스카이호크 테라퓨틱스, 인코포레이티드 스플라이싱을 조절하는 방법 및 조성물
KR20210135507A (ko) 2019-02-06 2021-11-15 스카이호크 테라퓨틱스, 인코포레이티드 스플라이싱을 조절하는 방법 및 조성물
JP2022537266A (ja) * 2019-06-19 2022-08-25 エフ．ホフマン－ラ ロシュ アーゲー デジタルバイオマーカー
EP3987543A1 (en) * 2019-06-19 2022-04-27 F. Hoffmann-La Roche AG Digital biomarker
US11918570B2 (en) 2020-04-13 2024-03-05 The Research Foundation For The State University Of New York Method of treatment for prevention of glucocorticoid toxicity and/or enhancement of muscle regeneration via neutrophil elastase inhibition
JP2023549455A (ja) * 2020-10-26 2023-11-27 スカラー ロック インコーポレイテッド 脊髄性筋萎縮症を治療するための抗プロミオスタチン／抗潜在型ミオスタチン抗体の使用
MX2023014840A (es) 2021-06-23 2024-02-12 Scholar Rock Inc Un inhibidor de la vía de la miostatina en combinación con un activador de la vía de la glp-1 para su uso en el tratamiento de trastornos metabólicos.
WO2023288277A1 (en) 2021-07-14 2023-01-19 Scholar Rock, Inc. Ltbp complex-specific inhibitors of tgfb1 and uses thereof
EP4426306A1 (en) * 2021-10-06 2024-09-11 F. Hoffmann-La Roche AG Novel combined administration
IL316463A (en) * 2022-05-04 2024-12-01 Scholar Rock Inc Using a myostatin inhibitor to treat spinal muscular atrophy
WO2024138076A1 (en) 2022-12-22 2024-06-27 Scholar Rock, Inc. Selective and potent inhibitory antibodies of myostatin activation

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
DE69233745D1 (de) 1991-12-02 2008-10-23 Cambridge Antibody Tech Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken
US5994618A (en) 1997-02-05 1999-11-30 Johns Hopkins University School Of Medicine Growth differentiation factor-8 transgenic mice
US7393682B1 (en) 1993-03-19 2008-07-01 The Johns Hopkins University School Of Medicine Polynucleotides encoding promyostatin polypeptides
US7566768B1 (en) 1995-10-26 2009-07-28 The Johns Hopkins University School Of Medicine Promyostatin peptides and methods of using same
WO1994021681A1 (en) 1993-03-19 1994-09-29 Johns Hopkins University School Of Medicine Growth differentiation factor-8
CA2194660C (en) 1994-07-08 2009-09-29 Se-Jin Lee Growth differentiation factor-11
US20030167492A1 (en) 1994-07-08 2003-09-04 Johns Hopkins University School Of Medicine Transgenic non-human animals expressing a gdf-11 dominant negative polypeptide, and methods of making and using same
US6656475B1 (en) 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
PT2275449T (pt) 2000-06-16 2016-12-27 Human Genome Sciences Inc Anticorpos que se ligam imunoespecificamente a blys
AU2011244851A1 (en) 2000-07-27 2011-11-24 The John Hopkins University School Of Medicine Promyostatin peptides and methods of using same
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
DE60128914T2 (de) 2001-10-05 2008-05-08 Affimed Therapeutics Ag Antikörper menschlichen Ursprungs zur Hemmung der Thrombozytenaggregation
US8455627B2 (en) 2001-10-05 2013-06-04 Affimed Therapeutics, Ag Human antibody specific for activated state of platelet integrin receptor GPIIb/IIIa
US20040044063A1 (en) 2002-05-31 2004-03-04 Brent Stockwell SMA therapy and cell based assay for identifying therapies
MY151032A (en) 2002-07-19 2014-03-31 Abbott Lab S A Treatment of tnf? related disorders
EP2192129A1 (en) 2002-09-16 2010-06-02 Johns Hopkins University Metalloprotease activation of myostatin, and methods of modulating myostatin activity
AR047392A1 (es) 2002-10-22 2006-01-18 Wyeth Corp Neutralizacion de anticuerpos contra gdf 8 y su uso para tales fines
RU2377253C2 (ru) 2002-12-02 2009-12-27 Амген Фремонт,Инк. Антитела, специфичные к фактору некроза опухолей, и их применение
BRPI0418317A (pt) 2003-12-31 2007-05-02 Schering Plough Ltd vacina de aumento de crescimento à base de epitopo de neutralização
EP3006039B1 (en) 2004-03-02 2021-01-06 Acceleron Pharma Inc. Alk7 polypeptides for use in promoting fat loss
WO2005103081A2 (en) 2004-04-20 2005-11-03 Genmab A/S Human monoclonal antibodies against cd20
JP2008500373A (ja) 2004-05-27 2008-01-10 アクセルロン ファーマ インコーポレーテッド ケルベロス（Ｃｅｒｂｅｒｕｓ）／ココ（Ｃｏｃｏ）誘導体およびそれらの使用
US7329737B2 (en) 2004-08-03 2008-02-12 Dyax Corp. Antibodies that bind hK-1
ES2395953T3 (es) 2005-01-26 2013-02-18 Amgen Fremont Inc. Anticuerpos frente a interleucina-1 beta
US20060216279A1 (en) * 2005-03-22 2006-09-28 Glass David J Myostatin inhibiting fusion polypeptides and therapeutic methods thereof
EP1877075A4 (en) 2005-04-25 2008-07-30 Pfizer ANTIBODY TO MYOSTATIN
EP2407486B1 (en) 2005-08-19 2017-11-22 Wyeth LLC Antagonist antibodies against GDF-8 and uses in treatment of ALS and other GDF-8-associated disorders
UA92504C2 (en) 2005-10-12 2010-11-10 Эли Лилли Энд Компани Anti-myostatin monoclonal antibody
WO2007061995A2 (en) 2005-11-21 2007-05-31 Novartis Ag Biomarkers for statin-induced myopathy or rhabdomyolysis
US8097596B2 (en) 2006-06-30 2012-01-17 Lakewood-Amedex, Inc. Compositions and methods for the treatment of muscle wasting
WO2008030367A2 (en) * 2006-09-01 2008-03-13 The General Hospital Corporation Selective myostatin inhibitors
US8895309B2 (en) 2006-11-29 2014-11-25 Nationwide Children's Hospital Myostatin inhibition for enhancing muscle and/or improving muscle function
EP2769731A1 (en) 2007-02-23 2014-08-27 The Trustees of Columbia University in the City of New York Methods to activate or block the HLA-E/QA-1 restricted CD8+ T cell regulatory pathway to treat immunological disease
JP5670179B2 (ja) 2007-03-30 2015-02-18 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 負の光学的分散を有する複屈折層
US7935687B2 (en) 2007-04-12 2011-05-03 Paratek Pharmaceuticals, Inc. Methods for treating spinal muscular atrophy using tetracycline compounds
CA2688563A1 (en) 2007-06-01 2008-12-11 Biogen Idec Ma Inc. Cripto binding molecules
TW200918553A (en) 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
PE20091163A1 (es) 2007-11-01 2009-08-09 Wyeth Corp Anticuerpos para gdf8
TW201029662A (en) 2008-12-19 2010-08-16 Glaxo Group Ltd Novel antigen binding proteins
JP5841845B2 (ja) 2009-02-24 2016-01-13 ソーク・インステチュート・フォー・バイオロジカル・スタディーズＳａｌｋ Ｉｎｓｔｉｔｕｔｅ Ｆｏｒ Ｂｉｏｌｏｇｉｃａｌ Ｓｔｕｄｉｅｓ ＴＧＦ−βスーパーファミリーのデザイナーリガンド
EP2424895B1 (en) 2009-04-27 2017-09-06 Novartis AG Compositions and methods for increasing muscle growth
CA2764890A1 (en) 2009-06-08 2010-12-16 Acceleron Pharma Inc. Methods for increasing thermogenic adipocytes
BR112012022672B1 (pt) 2010-03-10 2020-04-14 Genmab As anticorpo monoclonal, sequência de nucleotídeos, vetor de expressão, célula hospedeira procariótica recombinante, composição farmacêutica, uso do anticorpo, métodos para produzir um anticorpo, para detectar a presença de c-met em uma amostra, e, kit para detectar a presença de c-met em uma amostra
JO3340B1 (ar) 2010-05-26 2019-03-13 Regeneron Pharma مضادات حيوية لـعامل تمايز النمو 8 البشري
JP2013537425A (ja) 2010-08-16 2013-10-03 アムジエン・インコーポレーテツド ミオスタチンに結合するポリペプチド、組成物および方法
AU2012335541B2 (en) 2011-11-11 2017-07-06 Duke University Combination drug therapy for the treatment of solid tumors
US20130178454A1 (en) * 2011-11-17 2013-07-11 Shalender Bhasin Combination of testosterone and ornithine decarboxylase (odc) inhibitors
WO2013148284A1 (en) 2012-03-29 2013-10-03 Genentech, Inc. Antibodies that bind to a pcsk9 cleavage site and methods of use
WO2013165972A2 (en) 2012-04-30 2013-11-07 Cell Signaling Technology, Inc. Anti-hepatitis b virus antibodies and use thereof
WO2013186719A1 (en) 2012-06-15 2013-12-19 Pfizer Inc. Improved antagonist antibodies against gdf-8 and uses therefor
SG11201503271XA (en) 2012-11-06 2015-05-28 Scholar Rock Inc Compositions and methods for modulating cell signaling
CA2911105A1 (en) * 2013-05-01 2014-11-06 Genzyme Corporation Compositions and methods for treating spinal muscular atrophy
SG10201800800YA (en) 2013-05-06 2018-03-28 Scholar Rock Inc Compositions and methods for growth factor modulation
EP2853898B1 (en) 2013-09-27 2017-01-04 Medizinische Hochschule Hannover Analysis of myostatin in serum
WO2015070158A1 (en) 2013-11-11 2015-05-14 Sirna Therapeutics, Inc. Systemic delivery of myostatin short interfering nucleic acids (sina) conjugated to a lipophilic moiety
WO2015195094A1 (en) 2014-06-17 2015-12-23 Ember Therapeutics, Inc. Anti-activin and nati-myostatin antibodies and methods of using the same
EP3215175A4 (en) 2014-11-06 2018-06-27 Scholar Rock, Inc. Anti-pro/latent-myostatin antibodies and uses thereof
WO2016073906A2 (en) 2014-11-06 2016-05-12 Scholar Rock, Inc. Transforming growth factor-related immunoassays
AR103161A1 (es) 2014-12-19 2017-04-19 Chugai Pharmaceutical Co Ltd Anticuerpos antimiostatina y regiones fc variantes así como métodos de uso
CN107771081A (zh) * 2015-04-15 2018-03-06 瑞泽恩制药公司 用gdf8抑制剂增加力量和功能的方法
SMT202500263T1 (it) 2015-09-15 2025-09-12 Scholar Rock Inc Anticorpi anti-pro-miostatina/miostatina latente e loro usi
SG11201805709RA (en) 2016-01-08 2018-07-30 Scholar Rock Inc Anti-pro/latent myostatin antibodies and methods of use thereof
EP3785728A3 (en) 2016-06-13 2021-04-28 Scholar Rock, Inc. Use of myostatin inhibitors and combination therapies
JOP20190152A1 (ar) 2016-12-21 2019-06-20 Novartis Ag مضادات الميوستاتين، الآكتيفين أو مستقبلات الآكتيفين للاستخدام في علاج السمنة والحالات ذات الصلة

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ESTHER LATRES ET AL, "Myostatin blockade with a fully human monoclonal antibody induces muscle hypertrophy and reverses muscle atrophy in young and aged mice", SKELETAL MUSCLE, BIOMED CENTRAL LTD, (2015-10-09), vol. 5, no. 1, page 34 *
ZHIHUA FENG ET AL, "Pharmacologically induced mouse model of adult spinal muscular atrophy to evaluate effectiveness of therapeutics after disease onset", HUMAN MOLECULAR GENETICS, gb, (2016-03-01), vol. 25, no. 5, pages 964 - 975 *

Also Published As

Publication number Publication date
KR20230028813A (ko) 2023-03-02
US20190255093A1 (en) 2019-08-22
EP3368069B1 (en) 2020-08-05
AU2021261907B2 (en) 2024-06-06
JP2021063107A (ja) 2021-04-22
US20210283166A1 (en) 2021-09-16
AU2020210134A1 (en) 2020-08-13
MY185614A (en) 2021-05-25
CL2018003588A1 (es) 2019-03-01
JP7161554B2 (ja) 2022-10-26
PT3368069T (pt) 2020-11-11
EP4218804A3 (en) 2023-09-13
RS61090B1 (sr) 2020-12-31
HUE051480T2 (hu) 2021-03-01
SMT202000598T1 (it) 2021-01-05
NZ748917A (en) 2024-04-26
ES2830440T3 (es) 2021-06-03
WO2017218592A1 (en) 2017-12-21
JP7344337B2 (ja) 2023-09-13
US10946036B2 (en) 2021-03-16
KR102271635B1 (ko) 2021-07-06
KR20230169484A (ko) 2023-12-15
LT3368069T (lt) 2020-12-10
IL301468A (en) 2023-05-01
IL263510A (en) 2019-01-31
KR20210082548A (ko) 2021-07-05
AU2017283546A1 (en) 2018-12-20
AU2017283546B2 (en) 2020-05-21
JP2019523295A (ja) 2019-08-22
JP2023164920A (ja) 2023-11-14
AU2021261907A1 (en) 2021-12-02
CY1123678T1 (el) 2022-03-24
AU2020210134B2 (en) 2021-11-04
EP3785728A3 (en) 2021-04-28
EP4218804A2 (en) 2023-08-02
JP6823167B2 (ja) 2021-01-27
SI3368069T1 (sl) 2021-03-31
MY199499A (en) 2023-11-01
HRP20201764T1 (hr) 2020-12-25
DK3368069T3 (da) 2020-11-02
JP2022101593A (ja) 2022-07-06
KR20190017933A (ko) 2019-02-20
EP3368069A1 (en) 2018-09-05
PE20190205A1 (es) 2019-02-07
EP3785728A2 (en) 2021-03-03
AU2024203412A1 (en) 2024-06-27

Similar Documents

Publication Publication Date Title
AU2021261907B2 (en) Use of myostatin inhibitors and combination therapies
KR20180094110A (ko) 항-프로/잠재성 미오스타틴 항체 및 그의 사용 방법
JP7663559B2 (ja) Ａｃｔｒｉｉ受容体拮抗薬を含む肝疾患または肝臓障害の治療
ES2944357T3 (es) Tratamiento de enfermedades metabólicas inhibiendo la activación de miostatina
KR20230095998A (ko) 척수 근위축증을 치료하기 위한 항-프로/잠재성 마이오스타틴 항체의 용도
HK40097101A (en) Use of myostatin inhibitors and combination therapies
HK40043422A (en) Use of myostatin inhibitors and combination therapies
CN119451696A (zh) 肌生成抑制蛋白抑制剂用于治疗脊髓性肌肉萎缩的用途
JP2025183233A (ja) ミオスタチン阻害剤の使用および併用療法
HK1260302B (en) Use of myostatin inhibitors and combination therapies
HK1260302A1 (en) Use of myostatin inhibitors and combination therapies
NZ789268A (en) Use of myostatin inhibitors and combination therapies
NZ789250A (en) Use of myostatin inhibitors and combination therapies
NZ789269A (en) Use of myostatin inhibitors and combination therapies
RU2838150C1 (ru) Лечение заболевания или нарушения со стороны печени, предусматривающее применение антагонистов рецепторов actrii
Omosule The Effects of Differential and Combinatorial Inhibition of Myostatin and Activin a in the G610c Murine Model of Osteogenesis Imperfecta
US20250171526A1 (en) Treatment for Facioscapulohumeral Muscular Dystrophy (FSHD)

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 06 AUG 2020

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 06 AUG 2020

FGA Letters patent sealed or granted (standard patent)